Xlumena chases new funds with FDA approval for its AXIOS pancreatic stent

Xlumena's Axios stent and delivery system--Courtesy of Xlumena

The FDA has approved Xlumena's AXIOS stent and delivery system to treat pseudocysts of the pancreas. In its press release announcing the approval, the FDA noted the stent is the first pancreatic stent specifically designed to drain a pseudocyst.

The FDA approval followed hard upon Xlumena's announcement of new investors. Earlier this month, the Mountain View, CA, company announced a $25 million Series C round of financing led by Third Point LLC, the New York hedge fund run by Daniel Loeb.

It's not clear how large the U.S. market opportunity might be for AXIOS, which cleared EU regulators in 2011. Executives couldn't immediately be reached.

Pseudocysts form in the pancreas when gallstones or injuries block pancreatic ducts. Buildup of enzymes can form large pseudocysts, measuring 7 to more than 50 centimeters wide. Bacterial infections there can lead to life-threatening blood infections.

AXIOS stents are designed to drain fluids by establishing a temporary opening between the pancreas and the gastrointestinal tract.

Xlumena's investors also include Prism VentureWorks, Charter Life Sciences, Ascent Biomedical Ventures and Aperture Venture Partners.

- read the FDA press release

Suggested Articles

Synthetic DNA weaver Twist Bioscience announced a handful of new collaborations this week amidst a $140 million raise from an underwritten offering.

The FDA has announced a series of actions aimed at limiting the use of power morcellators in gynecologic surgeries.

J&J launched a virtual clinical study to gauge whether Apple’s iPhone and ECG-enabled smartwatch can help reduce the risk of stroke and catch AFib.